TCGA-CV-7177-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.151369863
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- CHOLESTEROL_HOMEOSTASIS+0.420
- TGF_BETA_SIGNALING+0.420
- ANGIOGENESIS+0.410
- UV_RESPONSE_DN+0.350
- HEDGEHOG_SIGNALING+0.340
- BILE_ACID_METABOLISM+0.330
- APICAL_JUNCTION+0.300
- COAGULATION+0.300
- APICAL_SURFACE+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.530
- E2F_TARGETS-0.460
- IL6_JAK_STAT3_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.420
- MYC_TARGETS_V2-0.420
- G2M_CHECKPOINT-0.370
- MYC_TARGETS_V1-0.370
- DNA_REPAIR-0.300
- INFLAMMATORY_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.870 |
| 2 | SRR8613707 | — | C | 0.865 |
| 3 | 20060030.TNBC | — | F | 0.861 |
| 4 | SRR8613758 | — | C | 0.854 |
| 5 | TCGA-FD-A3SM-01A-11R-A22U-07 | — | — | 0.845 |
| 6 | 20040084.LumA | — | A | 0.845 |
| 7 | SRR8613710 | — | F | 0.845 |
| 8 | SRR8518146 | — | F | 0.843 |
| 9 | TCGA-CV-7421-01A-11R-2081-07 | — | — | 0.826 |
| 10 | SRR8518453 | — | F | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |